The ATP assay, but not the MTT assay, detects further cytotoxicity of the combination of anthracycline-based therapy with histone deacetylase inhibitor (valproic acid) in breast cancer cells

Simple item page
dc.contributor.authorİlkay, Elif Armutak
dc.contributor.buuauthorArı, Ferda
dc.contributor.buuauthorUlukaya, Engin
dc.contributor.departmentUludağ Üniversitesi/Fen-Edebiyat Fakültesi/Biyoloji Bölümü.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyokimya Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-6729-7908tr_TR
dc.contributor.researcheridK-5792-2018tr_TR
dc.contributor.researcheridAAG-7012-2021tr_TR
dc.contributor.scopusid24376085300tr_TR
dc.contributor.scopusid6602927353tr_TR
dc.date.accessioned2022-06-24T08:02:07Z
dc.date.available2022-06-24T08:02:07Z
dc.date.issued2010
dc.description.abstractPurpose: It has been investigated that whether or not the combination of valproic acid (a histone deacetylase inhibitor) with anthracycline-based chemotherapy (FEC: 5-fluorouracil+epirubicine+ cyclophosphamide) would change the cytotoxic effects of FEC in breast cancer cells. Methods: The effect of valproic acid and its combination with FEC has been tested on MDA-MB-231 and MCF-7 human breast cancer cell lines. Anti-growth effects of treatments were determined by the MTT and ATP assays, while the detection of apoptosis was performed by the caspase-cleaved cytokeratin 18 assay. Results: Valproic acid treatment had anti-growth effect on the cell lines used at clinically achievable dose (0.6 mM). According to the MTT assay, the combination of valproic acid with different doses (50-200% Test Drug Concentration) of FEC did not result in any significant change over FEC-only treatment in both cell lines. However, according to the ATP assay, there has been found that the combination of 100% Test Drug Concentration FEC with valproic acid yielded more efficacy compared to FEC-alone. FEC induced the apoptosis in MCF-7 cells but the addition of valproic acid to FEC did not enhance apoptosis. Conclusion: According to the ATP assay, the use of valproic acid at the clinically achievable dose (0.6 mM) with different doses of FEC further increased the cytotoxic effect of FEC. However, this effect was not observed in the MTT assay. A caution should therefore be taken on the evaluation of the cytotoxic effect of valproic acid in cell lines.en_US
dc.identifier.citationArı, F. vd. (2010). "The ATP assay, but not the MTT assay, detects further cytotoxicity of the combination of anthracycline-based therapy with histone deacetylase inhibitor (valproic acid) in breast cancer cells". Turkish Journal of Biochemistry-Türk Biyokimya Dergisi, 35(4), 293-299.tr_TR
dc.identifier.endpage299tr_TR
dc.identifier.issn0250-4685
dc.identifier.issn1303-829X
dc.identifier.issue4tr_TR
dc.identifier.scopus2-s2.0-78651386909tr_TR
dc.identifier.startpage293tr_TR
dc.identifier.urihttps://web.citius.technology/upload/turkjbiochem/2010/293-299.pdf
dc.identifier.urihttp://hdl.handle.net/11452/27381
dc.identifier.volume35tr_TR
dc.identifier.wos000285648800002tr_TR
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherWalter De Gruyterde
dc.relation.collaborationYurt içitr_TR
dc.relation.journalTurkish Journal of Biochemistry-Türk Biyokimya Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectValproic aciden_US
dc.subjectBreast canceren_US
dc.subjectApoptosisen_US
dc.subjectFEC protocolen_US
dc.subjectM30 antigenen_US
dc.subjectCaspase-cleaved cytokeratin-18en_US
dc.subjectLuminescence assayen_US
dc.subjectCemotherapyen_US
dc.subjectGrowthen_US
dc.subjectAgenten_US
dc.subjectDrugsen_US
dc.subjectSerumen_US
dc.subjectBiochemistry & molecular biologyen_US
dc.subject.emtree3 (4,5 dimethyl 2 thiazolyl) 2,5 diphenyltetrazolium bromideen_US
dc.subject.emtreeAdenosine triphosphateen_US
dc.subject.emtreeAnthracycline derivativeen_US
dc.subject.emtreeBevacizumaben_US
dc.subject.emtreeCaspaseen_US
dc.subject.emtreeCyclophosphamideen_US
dc.subject.emtreeCytokeratin 18en_US
dc.subject.emtreeEpirubicinen_US
dc.subject.emtreeFluorouracilen_US
dc.subject.emtreeHistone deacetylase inhibitoren_US
dc.subject.emtreeTrastuzumaben_US
dc.subject.emtreeValproic aciden_US
dc.subject.emtreeAntineoplastic activityen_US
dc.subject.emtreeApoptosisen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeBreast canceren_US
dc.subject.emtreeCancer cell cultureen_US
dc.subject.emtreeCancer combination chemotherapyen_US
dc.subject.emtreeCancer growthen_US
dc.subject.emtreeCell strain MCF 7en_US
dc.subject.emtreeCell strain MDA MB 231en_US
dc.subject.emtreeCytotoxicityen_US
dc.subject.emtreeDrug effecten_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHuman cellen_US
dc.subject.emtreeHuman cell cultureen_US
dc.subject.emtreeImmunoassayen_US
dc.subject.emtreeIntermethod comparisonen_US
dc.subject.emtreeMonotherapyen_US
dc.subject.emtreeTherapy effecten_US
dc.subject.scopusHistone Deacetylase Inhibitors; Vorinostat; Romidepsinen_US
dc.subject.wosBiochemistry & molecular biologyen_US
dc.titleThe ATP assay, but not the MTT assay, detects further cytotoxicity of the combination of anthracycline-based therapy with histone deacetylase inhibitor (valproic acid) in breast cancer cellsen_US
dc.title.alternativeATP testi, MTT testinin aksine, meme kanseri hücrelerinde antrasiklin-bazlı tedavinin histon deasetilaz i̇nhibitörü ile kombinasyonunun yarattıǧı daha i̇leri düzeydeki sitotoksisiteyi tespit edebilmektediren_US
dc.typeArticle
dc.wos.quartileQ4en_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Arı_vd_2010.pdf
Size:
305.77 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus